Clinical trial · Observational
CYP19 Genetic Polymorphism & Aromatase Inhibitor(AI)
Significance of CYP19 Genetic Polymorphism on Musculoskeletal Symptom & Complication of Aromatase Inhibitor(AI)
NCT00973505CI-TRIAL-00002610AI-CYP19unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to investigate the relationship between the side effects(especially arthralgia and arthritis) which appear in the patients who are prescribed aromatase inhibitor(AI) and the CYP19 genetic polymorphisms.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Arthralgia | — | UNRESOLVED | — |
| Arthritis | — | UNRESOLVED | — |
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Genetic Polymorphism | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Aromatase Inhibitor(Femara or Arimidex) | Drug | Aromatase Inhibitor | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- CYP19
- description
- CYP19 genetic polymorphism
- interventionNames
- Drug: Aromatase Inhibitor(Femara or Arimidex)
Primary outcomes (1)
- measure
- Change of SNPs (PCR & sequencing), Estrogen, Inflammatory Cytokine level
- timeFrame
- 6, 12 months
Secondary outcomes (1)
- measure
- EORTC (European Organization for Research and Treatment of Cancer)- QOL(Quality of Life)- C30, BR23 & Skeletal pain information, BMI
- timeFrame
- 3,6,12 months
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. The patient must sign the informed consent. 2. The patient must sign the informed consent of genetic screening test. 3. The patient must be between 18 years old and 80 years old who can make a decision independently. 4. The patient must be post-menopause status. 5. The patient should be the stage 1,2 or 3 of the breast cancer. 6. The test result of the estrogen receptor or progesterone receptor is positive, so the patient should be taking the medication of AI (Aromatase Inhibitor). Exclusion Criteria: 1. The patient is pre-menopause status. 2. The test result of serum FSH level is below 30mU/ml. 3. The test result of the hormone receptor(ER \& PR) is negative or unknown. 4. Patient's breast cancer stage is 4 which has systemic metastatics.
References
Publications (0)
Data not yet available
No reference posted for this study.